Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Eptifibatide authorized for marketing in all E.U. member states

July 7, 1999

SmithKline Beecham and Fournier enter agreement for new antithrombotic

July 7, 1999

New cardiovascular disease candidate from Merck KGaA enters phase II

July 6, 1999

Novel glycoside antithrombotic agents in the pipeline at Gedeon Richter

July 6, 1999

Pharming begins phase I development of human lactoferrin

July 5, 1999

DuPont files NDA for Innohep for treatment and prevention of deep vein thrombosis

July 2, 1999

Corvas presents novel peptide aldehydes as thrombin inhibitors

July 1, 1999

Roberts buys rights to Agrylin from Bristol-Myers Squibb

June 29, 1999

One-year NINDS study results on t-PA for acute ischemic stroke

June 29, 1999

Thrombin-inhibitory anticoagulants prepared by Merck scientists

June 28, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...